SecBot SecBot
S-3 ·Filed Nov 13, 2026

LYEL

Lyell Immunopharma, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 10h ago SEC0001193125-26-460585
Shelf registration (potential dilution)
Actionable Insight • Neutral

The resale registration is a routine contractual step following the private placement. Monitor the pace of selling by the institutional holders listed in the filing, as their sales could create near-term overhang. The company's cash runway into 2028 reduces urgency for additional capital raises.

DirectionNeutral
Confidencehigh
Horizonweeks

ronde-cel

▲ Bullish Named in this S-3
Impact
Phase
Phase 3
Time to market
Pivotal data from the PiNACLE trial is expected mid-2027, with a BLA submission planned for the second half of 2027. If approved, commercial launch would likely follow in 2028.
Next catalyst
None dated

What to watchThe next major catalyst is the ASH 2026 Annual Meeting (December 12-15, 2026), where updated data from the PiNACLE pivotal trial (3L+) and the Phase 1/2 second-line cohort will be presented in oral and poster sessions. Strong data could drive the stock toward analyst targets (mean $37.88), while disappointing durability or safety signals would pressure shares. The pivotal data readout expected in mid-2027 and BLA submission in H2 2027 are the longer-term binary events.

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lyell Immunopharma filed an S-3 registration statement to register 7,428,040 shares of common stock for resale by selling stockholders who acquired them in a private placement that closed on November 4, 2026 at $10.77 per share. The company will not receive any proceeds from the resale; the filing is a contractual obligation under the securities purchase agreement. The private placement raised $80M (stated in the prior earnings report) and extends the company's cash runway into 2028.

Key Financial Metrics

Dilution
23.2%

Key Facts

  • S-3 registers 7,428,040 shares of common stock for resale by selling stockholders
  • Shares were issued at $10.77 per share in a private placement that closed November 4, 2026
  • Company will not receive any proceeds from the resale
  • Maximum aggregate offering price calculated at $114,540,376.80 based on $15.42 reference price
  • Selling stockholders include ARCH Venture Fund, T. Rowe Price, Caligan Partners, Euler Fund, Adage Capital, RTW Investments, Opaleye, Gates Frontier, Atlas Diversified, and Monashee Investment Management
  • Private placement raised $80M extending cash runway into 2028 (per cross-filing context)
  • Shares outstanding as of November 6, 2026: 32,015,715

Financial Impact

7,428,040 shares registered for resale, representing approximately 23.2% of shares outstanding at $10.77 per share (private placement price) or $114.5M at the $15.42 reference price used for SEC fee calculation

dilution

Risk Factors

  • Potential overhang from selling stockholders reselling 7.4M shares into the market
  • Company has filed 9 offering/registration filings in the last 24 months, indicating frequent capital market activity

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-460585
Document: d186264dexfilingfees.htm0001193125-26-460585
Document: d186264dex51.htm0001193125-26-460585
Document: d186264dex231.htm0001193125-26-460585
Document: 0001193125-26-460585-index-headers.html0001193125-26-460585
Document: 0001193125-26-460585-index.html0001193125-26-460585
Document: 0001193125-26-460585.txt0001193125-26-460585

Track record

21 reports on LYEL

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Neutral 3/10 Viewing Entry $14.30 Now $14.65 +2.45% settles Nov 17
  2. Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
  7. Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
  9. Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
  10. Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026